Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN ...

The ability to control gene expression across a wide range is crucial for many fields, including bioengineering, disease ...

Credit: BaLL LunLa / Shutterstock. Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN-101 DNA plasmid vaccine. The ...

Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN-101 DNA plasmid vaccine. The investigational vaccine, based on the ...

Get access to education webinars and virtual events, read the latest trending science news, and network with over 4.7 million people.

IMUNON (IMNN) announced new safety and immunogenicity data from ongoing analyses of results from the Company’s first Phase 1 proof-of-concept ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® ...

Marya Lieberman is a chemistry professor whose NIH-funded project is focused on developing a tool to detect poor-quality ...

What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation with Netflix ...